Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
317
Recruiting, any sponsor type, condition "hypertension"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting317
- Completed3,008
317 trials
Showing 1 to 25, recently updated first.
- Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)Pivotal-lookingRecruiting
Foresee Pharmaceuticals Co., Ltd.Industry
NCT06475781 · 126 participants (planned) · Start Mar 1, 2025 · Primary completion Feb 2028
Drug: Mirivadelgat; placebo · For: Group 3 Pulmonary Hypertension
Sites: Banja Luka, Bosnia and Herzegovina; Sarajevo, Bosnia and Herzegovina; Tbilisi, Georgia · 15 sites in all
National Institutes of Health Clinical Center (CC)NIH
NCT01712620 · 70 participants (planned) · Start Jan 10, 2014 · Primary completion Dec 31, 2031
Drug: Spironolactone; Placebo · For: Pulmonary Arterial Hypertension
Sites: Bethesda, Maryland
National Cancer Institute (NCI)NIH
NCT03206060 · 130 participants (planned) · Start Oct 10, 2017 · Primary completion Jan 1, 2030
Drug: Lu-177-DOTATATE; Ga-68-DOTATATE · For: Pheochromocytoma; Paraganglioma; Neuroendocrine Tumors and 1 more
Sites: Bethesda, Maryland
- SYH2062 Injection in Participants With Mild to Moderate Essential Hypertension .Pivotal-lookingRecruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07940075 · 360 participants (planned) · Start Aug 11, 2026 · Primary completion Jan 31, 2027
Drug: SYH2062; Placebo · For: Mild to Moderate Primary Hypertension
Sites: Beijing, China
AllRock Bio, Inc.Industry
NCT07175038 · 40 participants (planned) · Start Oct 1, 2025 · Primary completion Mar 2027
Drug: ROC-101 · For: Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension, Interstitial Lung Disease
Sites: Phoenix, Arizona; Rancho Cordova, California; Aurora, Colorado · 25 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07543120 · 323 participants (planned) · Start May 7, 2026 · Primary completion May 7, 2031
Drug: QCZ484 · For: Hypertension (HTN)
Sites: Andalusia, Alabama; Tucson, Arizona; Garden Grove, California · 46 sites in all
University of AarhusAcademic, hospital or other
NCT05834803 · 80 participants (planned) · Start Jun 26, 2023 · Primary completion Jun 1, 2027
Drug: Optimal medical therapy (OMT) · For: Renovascular Hypertension; Renovascular Hypertension With Renal Failure; Heart Failure and 1 more
Sites: Aarhus N, Denmark; Copenhagen, Denmark; Odense C, Denmark
- A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve DamagePivotal-lookingRecruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07770685 · 156 participants (planned) · Start Oct 7, 2026 · Primary completion Jul 31, 2030
Drug: ASP2767; Sham ASP2767 and 3 more · For: Glaucoma
Sites: Boston, Massachusetts
- Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseasePivotal-lookingRecruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07181109 · 11,000 participants (planned) · Start Sep 6, 2025 · Primary completion Sep 23, 2030
Drug: Zilebesiran; Placebo · For: High Risk Cardiovascular Disease; Hypertension; High Cardiovascular Risk
Sites: Birmingham, Alabama; Fairhope, Alabama; Foley, Alabama · 1,226 sites in all
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07064473 · 11,800 participants (planned) · Start Jul 22, 2025 · Primary completion Dec 14, 2029
Drug: Vicadrostat; Empagliflozin and 1 more · For: Diabetes Mellitus, Type 2; Hypertension; Cardiovascular Diseases
Sites: Anniston, Alabama; Fairhope, Alabama; Guntersville, Alabama · 1,142 sites in all
University of California, Los AngelesAcademic, hospital or other
NCT07168395 · 68 participants (planned) · Start Oct 1, 2026 · Primary completion Nov 2027
Drug: Non-selective beta blockers · For: Gastric Varices
Sites: Los Angeles, California
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07553442 · 93 participants (planned) · Start Apr 27, 2026 · Primary completion Apr 1, 2028
Drug: ALN-AGT01 RVR; Placebo and 1 more · For: Hypertension
Sites: Lake Forest, California; Tampa, Florida; Savannah, Georgia
- A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionRecruiting
CRISPR Therapeutics AGIndustry
NCT07758634 · 69 participants (planned) · Start Sep 25, 2026 · Primary completion Jul 1, 2028
Drug: CTX340; Placebo · For: Hypertension
Sites: Jacksonville, Florida; Orlando, Florida; Port Orange, Florida · 11 sites in all
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Pivotal-lookingRecruiting
Insmed IncorporatedIndustry
NCT07234032 · 344 participants (planned) · Start Jul 20, 2026 · Primary completion Jan 22, 2031
Drug: Treprostinil Palmitil Inhalation Powder; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease
Sites: Naples, Florida; Bend, Oregon; Prague, Czechia · 12 sites in all
Vanderbilt University Medical CenterAcademic, hospital or other
NCT03312556 · 12 participants (planned) · Start Sep 21, 2017 · Primary completion Dec 21, 2026
Drug: Placebo · For: Supine Hypertension; Autonomic Failure
Sites: Nashville, Tennessee
- A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood PressurePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06742723 · 5,000 participants (planned) · Start Mar 3, 2025 · Primary completion Dec 18, 2029
Drug: Baxdrostat/dapagliflozin; Placebo/dapagliflozin · For: Chronic Kidney Disease and Hypertension
Sites: Fairhope, Alabama; Sun City, Arizona; Tucson, Arizona · 771 sites in all
University of AlbertaAcademic, hospital or other
NCT07140484 · 27 participants (planned) · Start Oct 6, 2025 · Primary completion Jan 1, 2029
Drug: Sotatercept · For: Pulmonary Artery Hypertension
Sites: Edmonton, Canada
- The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial HypertensionPivotal-lookingRecruiting
Silvia UlrichAcademic, hospital or other
NCT07824674 · 20 participants (planned) · Start Oct 26, 2026 · Primary completion Apr 2028
Drug: Dextrose; Sildenafil 20mg · For: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Sites: Zurich, Switzerland
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07602166 · 20 participants (planned) · Start Oct 30, 2026 · Primary completion Jul 31, 2031
Drug: 2-hydroxybenzylamine; Placebo · For: Salt Sensitivity of Blood Pressure; High Blood Pressure; Inflammation and 1 more
Sites: Nashville, Tennessee
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07600723 · 30 participants (planned) · Start Oct 8, 2026 · Primary completion Apr 3, 2028
Drug: Sotatercept; Background PAH Therapy · For: Pulmonary Arterial Hypertension
Sites: Hyderabad, India; Belagavi, India; Chennai, India
- A Study of Modified Release RTN-001 In Patients With Uncontrolled HypertensionPivotal-lookingRecruiting
Retension Pharmaceuticals. Inc.Industry
NCT07142356 · 280 participants (planned) · Start Oct 31, 2025 · Primary completion Mar 2027
Drug: RTN-001; Matching placebo control · For: Uncontrolled Hypertension
Sites: Alexander City, Alabama; Birmingham, Alabama; Glendale, Arizona · 44 sites in all
- Statin Intervention for Severe Early-Onset Placental Insufficiency. (STATIN-PRE Trial)Pivotal-lookingRecruiting
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauAcademic, hospital or other
NCT07098975 · 154 participants (planned) · Start Jan 14, 2026 · Primary completion Nov 2027
Drug: Pravastatin 40 mg · For: Preeclampsia (PE); Intrauterine Growth Restriction (IUGR); Placental Insufficiency
Sites: Barcelona, Spain · 2 sites in all
Meshalkin Research Institute of Pathology of CirculationResearch network
NCT07914933 · 50 participants (planned) · Start Apr 29, 2025 · Primary completion Nov 2027
Drug: Infusion of levosimendan; Placebo infusion "Soluvit" · For: LEVOSIMENDAN; PULMONARY THROMBOENDARTERECTOMY; Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and 1 more
Sites: Novosibirsk, Russia
- Preeclampsia Intervention NetherlandsPivotal-lookingRecruiting
Amsterdam UMCAcademic, hospital or other
NCT06452498 · 180 participants (planned) · Start Sep 19, 2025 · Primary completion Mar 19, 2029
Drug: Metformin Hydrochloride; Placebo · For: Pre-Eclampsia Onset Less Than 37 Weeks; Pre-Eclampsia; Pre-Eclampsia; Complicating Pregnancy and 6 more
Sites: Amsterdam, Netherlands
- A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular EventPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07783802 · 120 participants (planned) · Start Aug 27, 2026 · Primary completion May 2027
Drug: Clazakizumab; Placebo · For: Atherosclerosis; Cardiovascular Disease; Obesity and 3 more
Sites: Huntsville, Alabama; Tucson, Arizona; Glendora, California · 46 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.